Clinical Trial Update: Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of fluzoparib and camrelizumab in nasopharyngeal carcinoma that progressed after first-line chemotherapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• Fluzoparib (fluzoparib)

Snippet

Sponsor: Fudan University | Conditions: Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | Phase 2 | Status: UNKNOWN